PDSB vs. AMLX, ACET, SGMT, KPTI, RNAC, CTXR, SCTL, GLYC, VTGN, and RPTX
Should you be buying PDS Biotechnology stock or one of its competitors? The main competitors of PDS Biotechnology include Amylyx Pharmaceuticals (AMLX), Adicet Bio (ACET), Sagimet Biosciences (SGMT), Karyopharm Therapeutics (KPTI), Cartesian Therapeutics (RNAC), Citius Pharmaceuticals (CTXR), Societal CDMO (SCTL), GlycoMimetics (GLYC), Vistagen Therapeutics (VTGN), and Repare Therapeutics (RPTX). These companies are all part of the "pharmaceutical preparations" industry.
Amylyx Pharmaceuticals (NASDAQ:AMLX) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking, profitability, risk and earnings.
Amylyx Pharmaceuticals has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
PDS Biotechnology received 34 more outperform votes than Amylyx Pharmaceuticals when rated by MarketBeat users. Likewise, 67.05% of users gave PDS Biotechnology an outperform vote while only 64.10% of users gave Amylyx Pharmaceuticals an outperform vote.
PDS Biotechnology has a net margin of 0.00% compared to PDS Biotechnology's net margin of -17.86%. PDS Biotechnology's return on equity of 3.92% beat Amylyx Pharmaceuticals' return on equity.
Amylyx Pharmaceuticals presently has a consensus price target of $32.67, suggesting a potential upside of 1,761.35%. PDS Biotechnology has a consensus price target of $17.33, suggesting a potential upside of 393.83%. Given PDS Biotechnology's higher probable upside, research analysts clearly believe Amylyx Pharmaceuticals is more favorable than PDS Biotechnology.
Amylyx Pharmaceuticals has a beta of -0.68, indicating that its stock price is 168% less volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500.
In the previous week, Amylyx Pharmaceuticals had 4 more articles in the media than PDS Biotechnology. MarketBeat recorded 14 mentions for Amylyx Pharmaceuticals and 10 mentions for PDS Biotechnology. Amylyx Pharmaceuticals' average media sentiment score of 0.46 beat PDS Biotechnology's score of 0.46 indicating that PDS Biotechnology is being referred to more favorably in the news media.
95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 11.7% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 10.0% of PDS Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Amylyx Pharmaceuticals beats PDS Biotechnology on 10 of the 17 factors compared between the two stocks.
Get PDS Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PDS Biotechnology Competitors List
Related Companies and Tools
